Several laboratories are currently synthesizing and test ing a variety of nicotinic agonists that may have thera peutic use for the treatment of Alzheimer's disease and other dementias, Parkinson's disease, Tourette's syn drome, tobacco dependence, and other disorders (1, 2). Anabaseine ( Fig. 1) , a neurotoxin present in certain animal venoms, has been a useful molecular model for nicotinic drug design (3, 4). It is a potent agonist at cer tain peripheral and central nicotinic receptors (5, 6; W.R. Kem et al., submitted). GTS-21 [3-(2,4-dimethoxybenzyl idene)anabaseine] (Fig. 1) , a benzylidene derivative of anabaseine that selectively activates central nicotinic receptors, is currently undergoing clinical tests as a pos sible means of ameliorating the cognitive impairment as sociated with Alzheimer's disease (7). This experimental drug possesses mixed agonist/antagonist properties. It is a partial agonist at a7-homo-oligomeric receptors but probably acts as a relatively weak antagonist on high affinity nicotinic receptors, since its maximum effect on a4,32-receptors expressed in the Xenopus oocyte was only about 4010 that of acetylcholine (ACh) (8). At much higher concentrations than are necessary to enhance cog nition, GTS-21 acts as a weak antagonist at peripheral nervous system nicotinic receptors (W.R. Kem et al., un published results). GTS-21 was found to improve several types of cognitive behavior in experimental mammals (6, 9, 10). The actions of nicotine and several related nicotinic agonists on cortical neurotransmitter levels have recently been investigated by in vivo microdialysis methods. Toide and Arima (11) were the first to show that nicotine elevated ACh in the rat frontal cortex. Toth et al. (12), who locally infused 1 mM nicotine through a microdialy sis tube into the rat frontal cortex, observed significant increases in dopamine (DA), serotonin (5-HT) and gluta mate, but not norepinephrine (NE); in their study, ACh was not measured. Ribeiro et al. (13) found that 4 mg/kg subcutaneous (s.c.) nicotine bitartrate elevated 5-HT for 120 min; this was blocked by prior administration of 5 mg/kg mecamylamine (Mec). Summers and Giacobini (14), using a much lower dose, found that s.c. ad ministered nicotine increased ACh, NE and DA levels but not 5-HT levels. Pretreatment with Mec prevented the nicotine stimulation of ACh, DA and NE levels. ACh and DA levels also increased significantly when nicotine was administered locally through the microdialysis probe (15). Several chemically related nicotinic agonists had different actions on the levels of these four neurotransmitters, perhaps by preferentially stimulating certain nicotinic receptor subtypes (16).
While the pharmacological properties of anabaseine have been investigated using a variety of in vitro prepara tions, its ability to alter neurotransmitter release in vivo has not been previously investigated. In the present study, we show that the broad spectrum nicotinic agonist anabaseine and the a7-selective agonist GTS-21 affect cortical neurotransmitter levels in very different ways. Some possible mechanisms that might explain these ob servations are presented in order to stimulate further in vestigation. 
Microdialysis surgery and experiments
Surgical procedures and experimental protocols closely followed those described by Summers et al. (14, 16) . Microdialysis probes (AN69HF) were inserted transverse ly into the cortices (A + 1.0, V -2.0 measured from the bregma) of male Sprague-Dawley rats weighing 250-400 g. Rats were allowed to recover overnight from surgery before the experiment. Injected compounds were dis solved in saline and subcutaneously (anabaseine and GTS-21) or intraperitoneally (Mec) administered in a volume of 2 ml/kg animal weight. The animals were awake and able to move within their respective cages during the experiment.
Measurements of neurotransmitter levels
Fractions of dialysate were collected every 30 min into vials containing 1.0 N acetic acid to prevent oxidation of catecholamines. Samples (4-6) were collected to establish basal neurotransmitter levels before administration of drug. Samples were split and run on two separated HPLC systems. One was coupled to a post-column immobilized enzyme reactor for ACh detection that contained acetyl cholinesterase to convert ACh to choline and choline oxi dase to convert the choline to betaine and electro chemically active hydrogen peroxide. The three biogenic amines were determined with a Coulochem II electro chemical detector (ESA, Bedford, MA, USA). Quan tification was achieved by comparing peak areas of the samples to a standard curve. See the previous paper (14) for a more detailed description of these methods.
Statistical analyses
Paired t-tests were used to assess the differences be tween baseline and post-injection time points within rats. Results are expressed as the mean ±S.E.M. and asterisks indicate points that are significantly (P<0.05) different from the baseline. Each mean value was obtained from six rats run in parallel.
RESULTS

A nabaseine effects
This toxin ( Fig. 2 ) significantly enhanced the extracel lular levels of both ACh (50070 increase from baseline) and NE (62070). It affected these two neurotransmitters in a manner similar to nicotine when applied in an equimolar (3.6 ,umol/kg) dose (16). DA and 5-HT concentrations were unaffected.
When administered 1.5 hr before anabaseine, Mec tial administration of Mec and anabaseine. Some of this increase apparently was in response to Mec alone.
GTS-21 effects
This 3-substituted anabaseine acted quite differently from anabaseine (Fig. 3) . ACh levels were not altered (except possibly at 30 min) when GTS-21 was ad ministered at the same 3.6 pmol/kg (1.37 mg/kg) dose. 5-HT concentration was also unaffected by GTS-21, as was previously observed with anabaseine and nicotine. However, NE (83% increase) and DA (96% increase) levels were significantly elevated by GTS-21, in contrast to the results with equimolar doses of anabaseine and nicotine.
When 1 mg/kg Mec was administered 1.5 hr before GTS-21 injection, remarkable increases in both ACh (25 fold) and 5-HT (13-fold) concentrations were observed (Fig. 3) . The two compounds together caused neurotrans mitter alterations that were not predicted from the data available on their actions when administered separately.
DISCUSSION
Anabaseine actions
Our microdialysis measurements showing anabaseine enhancement of extracellular ACh levels are the first in vivo evidence for an ACh releasing action of anabaseine, which was initially observed in vitro using an isolated rat cortex mince preparation (20). A number of laboratories have previously reported that nicotine and related com pounds release ACh from cortical slices, minces and syn aptosomes (see ref. 14 for pertinent references). Araujo et al. (21) showed that the ACh releasing action of the nicotinic agonist methylcarbamylcholine on a slice prepa ration was inhibited by some nicotinic antagonists known to affect a4~2 and 0P2-receptors, but was not inhibited by a-bungarotoxin, which inhibits a7-subunit-containing receptors. Anabaseine, like nicotine, is an agonist at these high affinity nicotinic receptors. In contrast, GTS-21 (see below) is an antagonist at these receptors but a partial agonist at a7-type receptors. That it did not increase ex tracellular ACh (Fig. 3) is consistent with the hypothesis that cholinergic neurons are primarily modulated by the high affinity nicotinic receptors.
In contrast with nicotine, anabaseine failed to elevate DA levels (14). Other experiments utilizing higher doses of anabaseine would be required to eliminate the pos sibility that this merely reflects a quantitative difference in sensitivity of this dopaminergic pathway to these nicotinic agonists.
Mec preadministration inhibited the ACh and NE elevating actions of anabaseine. It was previously shown that Mec administration alone at the dose employed here had little or no effect upon extracellular concentrations of the four neurotransmitters measured in the present study (14). However, Toide et al. (22) have found that 5 mg/kg Mec can elevate ACh levels. In the present experiments, Mec also produced some elevation in ACh, NE and DA levels (Figs. 2 and 3) .
Comparison of anabaseine and nicotine actions
The similar ACh and NE elevating actions of equimo lar doses of anabaseine and nicotine (14) suggest that these nicotinic agonists may be affecting levels of these two neurotransmitters through identical nicotinic recep tors. We suggest that these elevations are mediated by stimulation of high affinity nicotinic receptors, which in the rat cerebral cortex are predominantly (>90%) com posed of a4(32 subunits (23). Cholinergic neurons inner vating the frontal cortex project from the nucleus basalis of Meynert. Thalamic neurons with unidentified neuro transmitters which project to the cortex also possess nicotinic receptors (24) . Theoretically, nicotinic agonists could act upon nicotinic receptors on the cell bodies of the projecting cholinergic neurons as well as locally within the cortex upon nerve terminals. Although the affinity of anabaseine for a4~2-receptors is approximately sevenfold less than of nicotine (5, 6; W.R. Kem et al., submitted), anabaseine should penetrate the blood-brain barrier much more readily than nicotine because it is a significantly less polar compound. This may explain why an equimolar dose of anabaseine produced changes in transmitter concentrations very similar to that of nico tine. In addition, the 3.6 tmol/kg dose of nicotine was expected to produce a nearly maximal effect (15).
Nicotinic receptors located on cell bodies or terminals of non-cholinergic neurons represent other possible sites of action for nicotinic receptor agonists. Thus, actions of the two anabaseine compounds on NE and DA levels could be directly on neurons secreting these neuro transmitters. Since neither anabaseine nor nicotine (14) affected serotonin levels, serotoninergic neurons project ing from the raphe nuclei apparently lack sufficient num bers of nicotinic receptors to modulate the secretion of 5-HT.
GTS-21 actions
In contrast with anabaseine, GTS-21 probably acts es sentially as an antagonist on the a4(32 subtype, since its ability to stimulate these receptors is quite limited (7). However, like anabaseine, it possesses a high efficacy at homomeric a7-type receptors and a similar affinity for binding to a7-containing receptors in rat brain (6, 25). Thus, our failure to observe elevation of ACh with GTS 21, when administered alone, is consistent with the hypothesis stated above that a4(92-type receptors are dominant in mediating the enhancement of ACh release by nicotine, anabaseine and some other nicotinic agonists in the frontal cortex (16).
Other nicotinic receptor subtypes may also exist on adrenergic neurons, but the fact that GTS-21 (Fig. 3) en hances NE levels suggests that a7-receptors are involved. DA levels were elevated by GTS-21, in contrast with anabaseine, and this was reduced by preadministration of Mec.
Non-nicotinic sites of GTS-21 action GTS-21 may act at sites other than nicotinic cholinergic receptors. It has been found to interfere with the binding of several neurotransmitter radioligands to their respec tive receptors, but only at concentrations much higher (> 50 x) than are expected to occur in the present experi ments (6, 9, 10). Recent electrophysiological experiments (26) have also demonstrated that GTS-21 is also a weak antagonist at 5-HT3 receptors, which are homologous with nicotinic receptor subunits. Several 5-HT3 antago nists have been reported to stimulate the cortical release of ACh (27) . However, it seems rather unlikely that the cause of the massive elevation in 5-HT we observed after administration of both Mec and GTS-21 is due to its in hibition of 5-HT3 receptors because GTS-21 is only an effective antagonist at this receptor at concentrations Since GTS-21 did not affect ACh and 5-HT levels when administered alone, we were surprised that in the presence of Mec, GTS-21 caused a massive (25 and 13-fold, respectively) elevation in ACh and 5-HT levels. Although even a hypothetical basis for this phenomenon is current ly unavailable, we wish to briefly consider some factors that could contribute to this synergistic action.
In addition to their excitatory synaptic effects on neu rotransmitter release, some nicotinic agonists may also reduce release by stimulating inhibitory inputs to the neurons releasing the neurotransmitter. If Mec preferen tially blocks nicotinic receptors that reside on the inhibi tory neurons, it could greatly enhance the release of neurotransmitters whose secretion is normally limited by inhibitory interneuron modulation. GABAergic neurons are known to innervate and inhibit cholinergic neurons in the nbM which project to the cortex. It has recently been found that GABAergic interneurons in the interpeduncu lar nucleus and hippocampus possess high nicotine affin ity receptors which when activated cause an increase in GABA secretion (28) (29) (30) . We suggest that Mec, at the dose employed in our study, preferentially reduced nico tinic activation of GABAergic neuron high affinity nico tine receptors, without greatly affecting the a7-containing receptors. At the dose we used, GTS-21 was only expected to block some of the high affinity receptors.
Although there is still little published data concerning the relative susceptibility of different nicotinic receptor channels to Mec blockade, current data on the human receptors suggests that there are large differences in sen sitivity between nicotinic receptors for this compound. The sensitivity of rat PC12 cell autonomic nicotinic receptors (mostly composed of a3 and f34 subunits) to Mec was over 100 x higher than that of human neuro muscular nicotinic receptors (31) . This is consistent with its previous use as an anti-hypertensive drug. While the sensitivities of rat nicotinic receptors to Mec are still unknown, the human a7-receptor (32) has recently been reported to have a Mec IC50 of 1.8 pM, which is about tenfold lower sensitivity than the PC 12 (rat) receptor and about a tenfold higher sensitivity relative to the human neuromuscular nicotinic receptor (31) . It is known that high concentrations of Mec will block both a bungarotoxin-inhibitable (probably a7) and high affinity (probably a4(32) nicotinic receptors residing on cultured hippocampal neurons (33) . Several laboratories have also reported that nicotine stimulated behaviors and physio logical effects were blocked by quite different concentra tions of Mec (34) . For instance, sensory gating in rats was only affected by Mec doses of 5 mg/kg and higher (35, 36) . The NMDA-type glutamate channel is also inhibited by relatively large concentrations of Mec, which further complicates the interpretation of in vivo data (37, 38) .
Quantitative comparisons of the ability of Mec to block different rat nicotinic receptor channels in vitro are need ed to determine whether our assumption that the a7-con taining receptors are less susceptible than the a4(32-recep tors is valid. For some time it has been known that 5-HT2 receptors are located near or on cholinergic nerve terminals in the rat cortex (39) . It has very recently been shown that ACh release in the rat frontal cortex can be enhanced by stimulation of the lB and 2A subtypes of 5-HT receptors, as well as by inhibition of 5-HT3 receptors (40, 41) . Thus it is possible that enhancement of 5-HT levels by the GTS-21 plus Mec combination would further enhance ACh release. If this were the case, then selective antago nists for the 113 and 2A serotonin receptors would be ex pected to diminish the massive ACh increase we observed with these two compounds.
Large increases in frontoparietal cortex ACh levels have also been observed after administration of muscar inic antagonists alone (42) or concomitantly with nicotine (43). Quirion et al. (43) have suggested that blockade of muscarinic M2 type autoreceptors on cholinergic nerve terminals and concomitant stimulation of neuronal nico tinic receptors may be a useful therapeutic strategy for ameliorating a decreased cholinergic function in Alzhei mer's dementia. It is also conceivable that co-administra tion of GTS-21 and Mec might significantly enhance cog nition by simultaneously increasing both ACh and 5-HT levels.
More intensive microdialysis investigations of the ac tions of these and other nicotinic compounds upon neu rotransmitter levels in relevant regions of the brain could shed new light on the mechanisms by which nicotinic receptors influence neurochemical mechanisms involved in cognition. 
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